American Well Co. (NYSE:AMWL) Receives $11.90 Consensus PT from Analysts

American Well Co. (NYSE:AMWL) has received an average rating of “Hold” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $11.90.

A number of brokerages have recently commented on AMWL. Stifel Nicolaus increased their target price on shares of American Well from $9.00 to $10.00 and gave the company a “hold” rating in a research report on Thursday, February 13th. Truist Financial raised their price objective on shares of American Well from $10.00 to $12.00 and gave the stock a “hold” rating in a research report on Friday, February 14th. Needham & Company LLC restated a “hold” rating on shares of American Well in a research report on Thursday, February 13th. Wells Fargo & Company upgraded shares of American Well from an “equal weight” rating to an “overweight” rating and set a $15.00 price objective for the company in a research report on Monday, January 13th. Finally, Morgan Stanley cut their price objective on shares of American Well from $20.00 to $10.50 and set an “equal weight” rating for the company in a research report on Tuesday, December 17th.

American Well Stock Down 3.0 %

AMWL opened at $7.90 on Tuesday. The company has a market cap of $123.27 million, a price-to-earnings ratio of -0.56 and a beta of 1.18. American Well has a 52-week low of $5.00 and a 52-week high of $18.80. The firm’s fifty day simple moving average is $9.95 and its two-hundred day simple moving average is $9.31.

American Well (NYSE:AMWL) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($2.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.04) by $0.27. American Well had a negative net margin of 81.83% and a negative return on equity of 56.73%. On average, research analysts forecast that American Well will post -9.34 EPS for the current year.

Insider Buying and Selling

In other American Well news, insider Phyllis Gotlib sold 4,781 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.80, for a total transaction of $42,072.80. Following the sale, the insider now owns 147,998 shares of the company’s stock, valued at approximately $1,302,382.40. This trade represents a 3.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 5,219 shares of company stock worth $46,454 over the last 90 days. 12.80% of the stock is owned by insiders.

Institutional Trading of American Well

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AMWL. 4D Advisors LLC acquired a new stake in American Well during the fourth quarter worth approximately $1,088,000. Takeda Pharmaceutical Co. Ltd. acquired a new stake in American Well during the fourth quarter worth approximately $564,000. Senvest Management LLC raised its holdings in American Well by 3.9% during the fourth quarter. Senvest Management LLC now owns 1,300,611 shares of the company’s stock worth $9,429,000 after purchasing an additional 48,800 shares in the last quarter. HighTower Advisors LLC acquired a new stake in American Well during the third quarter worth approximately $355,000. Finally, Norges Bank acquired a new position in shares of American Well in the 4th quarter valued at $204,000. Institutional investors and hedge funds own 56.05% of the company’s stock.

About American Well

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members.